Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (2013 - 2026)

Tandem Diabetes Care has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$20.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 84.38% year-over-year to -$20.4 million; the trailing twelve-month figure through Mar 2026 stood at -$94.5 million (up 48.59% YoY), and the FY2025 full-year result was -$204.7 million, down 113.18% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$20.4 million, down from -$543000.0 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $769000.0 in Q4 2024, with the low at -$130.6 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$37.5 million across 5 years, with a median of -$30.0 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 951.95% — and 2024, when it jumped 102.56%.
• Tandem Diabetes Care's Net Income towards Common Stockholders stood at -$15.9 million in 2022, then slumped by 89.31% to -$30.0 million in 2023, then surged by 102.56% to $769000.0 in 2024, then tumbled by 170.61% to -$543000.0 in 2025, then sank by 3655.62% to -$20.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$20.4 million (Q1 2026), -$543000.0 (Q4 2025), and -$21.1 million (Q3 2025), per Business Quant data.